Navigation Links
YM BioSciences announces controlled equity offering
Date:4/26/2010

MISSISSAUGA, ON, April 26 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE YMI, TSX:YM), announced today that it has filed a prospectus supplement to its final base shelf prospectus, dated September 16, 2009, with the Ontario Securities Commission, and a supplement to its U.S. prospectus, dated September 16, 2009, forming part of its U.S. registration statement, with the United States Securities and Exchange Commission.

YM has entered into a Sales Agreement, dated April 23, 2010, with Cantor Fitzgerald & Co., under which YM may, at its discretion, from time to time sell up to a maximum of 7,750,000, of its common shares through an "at-the-market" equity offering program known as a Controlled Equity Offering ("CEO"). Cantor Fitzgerald & Co. will act as sales agent for any sales made under the CEO. The common shares will be sold at market prices prevailing at the time of a sale (if any) of the common shares or at prices negotiated with Cantor Fitzgerald & Co., and, as a result, prices may vary as between purchasers and during the period of the offering. The Company is not required to sell any of the reserved shares at any time during the term of the CEO, which extends until October 16, 2011, and there are no stand-by fees for having established the arrangement. The Sales Agreement does not prohibit the Company from conducting additional financings.

The Canadian prospectus and prospectus supplement have been filed on SEDAR and the U.S. prospectus and the supplement thereto have been filed on the SEC's website (

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
2. NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
3. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
4. YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations
5. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
6. YM BioSciences closes US$17.5 million financing
7. YM BioSciences to raise approximately US$15 million
8. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
9. TEI Biosciences PriMatrix(TM) Awarded Seal of Approval by American Podiatric Medical Association
10. YM BioSciences presents CYT387 and CYT997 data at international cancer conference
11. YM BioSciences granted two US patents for AeroLEF(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... This webinar will focus on EMA ... assessment in biosimilars. , Regulatory frameworks are evolving many ... however the complex nature of biopharmaceuticals makes the demonstration ... extremely challenging. Based on the specific aspects of biosimilar ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... 2014 AudioNotch is the internet's leading ... the treatment of tinnitus. Patients listen to sound therapy ... a period of weeks to months, their tinnitus volume decreases. ... forms: Notched Music and Notched White Noise. Now, AudioNotch is ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Zentaris Inc.,(NASDAQ: AEZS , TSX: AEZ), a ... will announce its third quarter 2008,financial and operating ... a.m.,The Company will host a conference call and ... at 10:00 a.m., Eastern Time., Participants may ...
... -- China Shenghuo,Pharmaceutical Holdings, Inc. (Amex: ... is engaged in the research, development, manufacture, ... products,in the People,s Republic of China, today ... the American Stock Exchange) (the "Exchange") has ...
... Make Diabetes a Smaller Part of Life, BEDFORD, ... the leader in patch pump technology with its OmniPod(R),Insulin ... Part of Your Life, video contest. The competition begins ... all current OmniPod users.,Entrants are invited to create a ...
Cached Biology Technology:NYSE Alternext US Accepts China Shenghuo's Compliance Plan for Continued Listing 2NYSE Alternext US Accepts China Shenghuo's Compliance Plan for Continued Listing 3NYSE Alternext US Accepts China Shenghuo's Compliance Plan for Continued Listing 4Video: Insulet Unveils Video Contest for OmniPod Users 2Video: Insulet Unveils Video Contest for OmniPod Users 3
(Date:4/24/2014)... International Glossina Genome Initiative (IGGI) has produced the first ... morsitans . The blood-sucking insect is the sole transmitter ... sub-Saharan Africa. The vast store of genetic data will ... and provide insights into the tsetse fly,s unique biology. ... insect world: it feeds exclusively on the blood of ...
(Date:4/24/2014)... Publishing recently introduced Clinical OMICs ... application of OMICs technologies in clinical settings. These ... to transform medical care just as they revolutionized ... , "GEN,s editors and reporters have written about ... etc. etc. for years," said John Sterling, editor-in-chief ...
(Date:4/24/2014)... research led by Alison Allan, PhD, a scientist at ... why breast cancer often spreads or metastasizes to the ... cancer and the number two cause of cancer-related deaths ... traditional chemotherapy and radiation have a high success rate, ... conventional treatments fail. In particular, the lung is one ...
Breaking Biology News(10 mins):Genetic code of the deadly tsetse fly unraveled 2New study helps to explain why breast cancer often spreads to the lung 2
... NY In the neuromuscular disease called spinal muscular ... single gene mutation leads to serious damage in growing ... Now, in laboratory experiments, researchers at Cold Spring Harbor ... replenish the protein by activating an existing, slightly modified ...
... WI, APRIL 4, 2008 The American Society ... (CSSA), and Soil Science Society of America (SSSA) ... as part of the 2008 National Student Recognition ... the Societies news magazine. The 2008 National ...
... some people are born with silver spoons in their ... of the animal world, according to research done in ... of female red squirrels in Kluane, Yukon, revealed that ... spring temperature experienced between birth and weaning could reflect ...
Cached Biology News:Cold Spring Harbor Laboratory scientists devise potential approach to treat spinal muscular atrophy 2Outstanding undergraduates recognized in agronomy, crop, soil, and environmental sciences 2
Template and primers for preparation of internal control spots...
Biotin-OSu is used to label proteins, immunological agents, DNA and synthetic oligonucleotides. Biotin labeling is detected through enzymatically labeled avidin or streptavidin proteins that conforma...
Reusble. Uses in conjunction with the Apoptotic Cell Isolation Kit....
RAT ANTI MOUSE JAM-2 Immunogen: Recombinant soluble JAM-2...
Biology Products: